NEW YORK – NeuMoDx Molecular and Sentinel Diagnostics have formed a partnership to develop new molecular diagnostics assays, the companies announced Monday. The assays will be for the detection and monitoring of post-transplant infections, parasitic and hospital acquired infections, and respiratory infections; and for pharmacogenetics applications, the firms said in a statement.